通络胶囊治疗急性冠状动脉综合征心肌梗死疗效观察

Observation on curative effects of Tongluo capsule(通络胶囊) on myocardial infarction in patients with myocardial infarction and acute coronary syndrome

目的:观察通络胶囊对急性心肌梗死QT离散度、血栓素A2 、6酮前列腺素F1α和C反应蛋白的影响。方法:6 1例急性冠状动脉综合征心肌梗死患者被随机分为治疗组与对照组。两组均给予溶栓、扩张冠脉、抗凝、调脂等治疗。在此基础上,治疗组口服通络胶囊30 d,分别于治疗前、治疗15 d、治疗30 d后检测两组患者QT离散度、血栓素、前列腺素和C反应蛋白。结果:与对照组比较,治疗组治疗后血栓素B2 〔(2 88.77±33.2 ) ng/ L比(32 4 .6 9±33.6 7) ng/ L〕、C反应蛋白〔(2 2 .77±7.2 8) m g/ L比(36 .15±9.39) m g/ L〕及QT离散度(0 .0 6 4±0 .0 16比0 .0 73±0 .0 0 9)均明显降低(P均<0 .0 5 ) ,6酮前列腺素F1α明显升高〔(134.0 0±2 2 .0 4 ) ng/ L比(10 2 .14±30 .4 7) ng/ L ,P<0 .0 5〕。结论:通络胶囊对心肌梗死患者有降低恶性心律失常发生率、稳定斑块、改善预后等积极作用。

Objective: To observe the effects of Tongluo capsule(通络胶囊) on QT disperse(QTd), thromboxane A 2(TXA 2), 6ketoprostaglandin F 1α(6ketoPGF 1α) and C reactive protein(CRP) in acute myocardial infarction (AMI) patients. Methods: Sixty one AMI patients with acute coronary syndrome were randomly divided into treatment group and control group. Patients in both groups were treated with routine treatment, such as thrombolytic treatment, dilation of coronary artery, anticoagulation, regulating hyperlipidemia. Additionally, the treatment group was treated with Tongluo capsule for one month. QTd, TXA 2, 6ketoPGF 1α and CRP were detected before treatment and 0.5 and 1 month after the treatment. Results: Compared with the control group, TXB 2〔(288.77±33.2)ng/L vs. (324.69±33.67)ng/L〕, CRP〔(22.77±7.28)mg/L vs. (36.15±9.39)mg/L〕 and QTd (0.064±0.016 vs. 0.073±0.009) were all decreased after treatment in the treatment group (all P<0.05), but 6ketoPGF 1α elevated significantly 〔(134.00±22.04) ng/L vs. (102.14±30.47)ng/L, P<0.05〕. Conclusion: Tongluo capsule has the effects of lowing the incidence of arrhythmia, stabilizing endothelial cell and improving progress.